ESR2 and neoplasm: Also, Erb-IL-21 presented much lower toxicity than Erb-IL-2, even at high doses and intraperitoneal treatment with Erb-IL-21 limited the tumor growth in well-established tumor models (MC38-cEGFR, B16-cEGFR, and Ag104Ld-cEGFR).